Alison Kanski

Articles Authored by Alison Kanski
Role of SPOP Mutations in Prostate, Endometrial Cancer Come Into Focus in Retrospective Analysis
Premium
Using Caris Life Sciences' database, researchers found that prostate and endometrial cancers with SPOP mutations have distinct immune characteristics.

Mass General Tries to Show Value of Virtual Precision Medicine Clinic to Community Oncologists
Premium
The virtual clinic helped community oncologists interpret genomic testing results and led a third of cases to be enrolled in precision medicine drug trials.

Study Secures EGFR Mutation's Role in Inherited Lung Cancer Risk; Raises Questions About Guidelines
Premium
In a prospective study, patients with an EGFR T790M somatic mutation at diagnosis had a 50 percent chance of having a germline mutation, suggesting the need for more specific guidelines.

AccessHope Real-World Data Study Identifies Molecular Testing Gaps in Pancreatic Cancer Care
Premium
Out of around 100 cases reviewed by subspecialists, most completed recommended, guideline-concordant germline and somatic testing, but many still did not.

Pfizer Oncology Revenues Fall 6 Percent as Firm Anticipates Seagen Acquisition
Several of Pfizer's precision oncology products including Ibrance, Xalkori, and Braftovi saw declines in Q3.

Executives noted that its two recent acquisitions, Mirati Therapeutics and Turning Point Therapeutics, underscore its shift away from immunotherapy.

Amgen Eager for Regulatory Discussions After Lumakras-Vectibix CodeBreaK 300 Data in Colon Cancer
Premium
At ESMO, experts found the combination promising in KRAS G12C-mutated colorectal cancer patients, though some want more safety and overall survival data.

Experts at ESMO said the MARIPOSA studies support Rybrevant combinations as potential options for NSCLC, but survival data and patient stratification are needed.
Next-Gen KRAS Inhibitors Show Initial Efficacy Across Different Tumors, Variants in ESMO Studies
Premium
Researchers presented data on new KRAS-targeted drugs and combinations from Revolution Medicines, Jacobio Pharma, Jiangsu HengRui Medicine, and InventisBio.

Roche's Alecensa Lowers Recurrence in Adjuvant NSCLC, But Experts Await Overall Survival Data
Premium
In a discussion of the ALINA trial results at ESMO, an expert suggested oncologists shouldn't stop offering adjuvant chemotherapy just yet.
